
Conference Coverage
about 4 hours ago
Step Therapy Can Disrupt Cancer Treatment: Alyssa Schatz, DrPH, MSWabout 5 hours ago
New Mechanism of DME Treatment Highlights Clinical Trial Updatesabout 6 hours ago
Putting an ROI on AI in Community Oncology: Larry Bilbreyabout 21 hours ago
Using Complement Inhibitors in GA Comes With Pros and ConsLatest Content

Rosacea Likely Underdiagnosed in Patients With Skin of Color

Early HS Treatment May Prevent Scarring in Patients With Skin of Color

Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV

Polyphenols Show Promise in Endometriosis But Lack Clinical Proof

E-Cigarettes, Depression Showed Association With Cataracts, Cataract Surgery

Shorts










Center on Health Equity & Access
All News

The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).

Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.

An intraoperative indocyanine green (ICG) fluorescence imaging protocol in sarcoma surgery detected 14 of 15 positive margins vs 4 of 15 for surgeons, though its specificity was 41.7% vs 88.9%.

Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.

A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.

The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.

Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.

Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.

TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.




























